Suppr超能文献

在经动脉肝化学灌注治疗前的乳酸脱氢酶水平可预测葡萄膜黑色素瘤肝转移患者的生存和进展时间。

Lactate Dehydrogenase Prior to Transarterial Hepatic Chemoperfusion Predicts Survival and Time to Progression in Patients with Uveal Melanoma Liver Metastases.

机构信息

Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany.

Clinic for Diagnostic and Interventional Radiology/Neuroradiology, Sankt-Elisabeth-Hospital Gütersloh, Gütersloh, Germany.

出版信息

Rofo. 2021 Jun;193(6):683-691. doi: 10.1055/a-1299-1627. Epub 2020 Dec 21.

Abstract

PURPOSE

To assess serum lactate dehydrogenase (LDH) as a pretreatment prognostic factor in patients with uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion (THC).

MATERIALS AND METHODS

56 patients (48 % male, median age: 63.5 years) underwent a median of 4 THC sessions. Kaplan-Meier for median overall survival (OS) and time to hepatic progression (TTP; 95 %CI) in months and Cox proportional hazards model for uni- (UVA) & multivariate analyses (MVA) for hazard ratio (HR) evaluation were calculated.

RESULTS

The median OS was 9.4 months. The pretreatment LDH value before 1st THC was the strongest OS predictor with 19.8 months for normal (≦ 280 units per liter (U/L)), 9.7 for intermediate (> 280-< 1000 U/L), and 3.84 months for high (≧ 1000 U/L) LDH. LDH significantly predicted a median TTP with 8 months, 4 months, and 1 month for normal, intermediate, and high LDH, respectively. UVA revealed intermediate (16.5) and high (77.3) LDH, bilirubin > the upper limit of normal (ULN) (2.89), alkaline phosphatase > 1.5 ULN (6.8), leukocytes > ULN (4.2), gamma-glutamyl transferase (GGT) > ULN (7), extrahepatic metastases (1.8) and liver lesions ≥ 5 cm (3.6) as significant predictors for worse OS. MVA confirmed intermediate (5) and high (27.1) LDH, bilirubin (5.7), GGT (2.9), and tumor size ≥ 5 cm (3.7) as significant independent predictors for worse OS. Patients with decreasing vs. increasing LDH > 10 % between 1st and 2nd THC (median: 38 days) survived longer (14.6 vs. 4.3 months) and progressed later (7 months vs. 1 month).

CONCLUSION

Elevated pretreatment serum LDH is an essential and robust OS and TTP predictor, potentially allowing for the identification of patients benefiting most from transarterial hepatic chemoperfusion.

KEY POINTS

· Pretherapeutic LDH is the most reliable prognosticator for OS and TTP. · Therapy-related LDH decrease > 10 % between 1st and 2nd THC had prolonged OS and TTP. · Lower Values of LDH, bilirubin, gamma-glutamyl transferase, and tumor size are independent pretherapeutic predictors for longer OS. · Extrahepatic metastases do not have an independent influence on overall survival.

CITATION FORMAT

· Ludwig J, Haubold J, Heusner T et al. Lactate Dehydrogenase Prior to Transarterial Hepatic Chemoperfusion Predicts Survival and Time to Progression in Patients with Uveal Melanoma Liver Metastases. Fortschr Röntgenstr 2021; 193: 683 - 691.

摘要

目的

评估血清乳酸脱氢酶(LDH)作为接受经肝动脉化学灌注(THC)治疗的葡萄膜黑色素瘤肝转移患者的预处理预后因素。

材料和方法

56 名患者(48%为男性,中位年龄:63.5 岁)接受了中位数为 4 次 THC 治疗。计算中位总生存期(OS)和肝进展时间(TTP;95%CI)的 Kaplan-Meier 分析(以月表示)和单变量分析(UVA)和多变量分析(MVA)的 Cox 比例风险模型用于危险比(HR)评估。

结果

中位 OS 为 9.4 个月。第一次 THC 前的预处理 LDH 值是 OS 的最强预测因子,正常(≦280 单位/升(U/L))为 19.8 个月,中等(>280-<1000 U/L)为 9.7 个月,高(≧1000 U/L)为 3.84 个月。LDH 显著预测中位 TTP,正常、中等和高 LDH 分别为 8 个月、4 个月和 1 个月。UVA 显示中间(16.5)和高(77.3)LDH、胆红素>正常值上限(ULN)(2.89)、碱性磷酸酶>1.5 ULN(6.8)、白细胞>ULN(4.2)、γ-谷氨酰转移酶(GGT)>ULN(7)、肝外转移(1.8)和肝病变≥5cm(3.6)是 OS 较差的显著预测因子。MVA 证实中间(5)和高(27.1)LDH、胆红素(5.7)、GGT(2.9)和肿瘤大小≥5cm(3.7)是 OS 较差的独立预测因子。与第 1 次和第 2 次 THC 之间 LDH 升高>10%(中位数:38 天)的患者相比,LDH 降低的患者存活时间更长(14.6 个月 vs. 4.3 个月),进展时间更晚(7 个月 vs. 1 个月)。

结论

升高的预处理血清 LDH 是 OS 和 TTP 的重要且强大的预测因子,可能有助于识别最受益于经肝动脉化学灌注的患者。

关键点

· 治疗前 LDH 是 OS 和 TTP 最可靠的预后指标。

· 第 1 次和第 2 次 THC 之间 LDH 下降>10%可延长 OS 和 TTP。

· LDH、胆红素、γ-谷氨酰转移酶和肿瘤大小较低是 OS 延长的独立预测因子。

· 肝外转移对总生存期无独立影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验